| AJNMMI Copyright © 2011-present, All rights reserved. Published by e-Century Publishing Corporation, Madison, WI 53711, USA |
Am J Nucl Med Mol Imaging 2011;1(1):47-53.
Review article
18F-FDG PET in sarcoma treatment response imaging
Janet F Eary, Douglas S Hawkins, Eve T Rodler, Ernest U Conrad, III
University of Washington, Departments of Radiology, Orthopedics, and Pathology; Seattle Children’s Hospital, Division of Oncology;
Seattle Children’s Hospital, Division of Hematology/Oncology; Seattle Cancer Care Alliance; University of Washington, Medical
Oncology Division; University of Washington, Department of Orthopedics and Sports Medicine; Seattle Children’s Hospital, Pediatric
Orthopedics, Seattle, WA, USA.
Received May 4, 2011; accepted June 22, 2011; Epub June 23, 2011; Published August 1, 2011
Abstract: Sarcomas are a biologically complex group of diseases that exhibit variable responses to single or combination therapy.
18F-FDG PET imaging contributes to sarcoma treatment response assessment as an objective semi-quantitative biomarker of
response. In this review, background and experience in 18F-FDG PET as a biomarker that successfully identifies tumor response is
assessed. (ajnmmi1105001).
Keywords: 18F-FDG PET, sarcoma, imaging treatment response
Full text PDF
Address all correspondence to:
Janet F. Eary, MD
University of Washington Medical Center
1959 NE Pacific St., Rm. AA011, Box 356113
Seattle, WA 98195-6113, USA.
E-mail: jeary@u.washington.edu
Review article
18F-FDG PET in sarcoma treatment response imaging
Janet F Eary, Douglas S Hawkins, Eve T Rodler, Ernest U Conrad, III
University of Washington, Departments of Radiology, Orthopedics, and Pathology; Seattle Children’s Hospital, Division of Oncology;
Seattle Children’s Hospital, Division of Hematology/Oncology; Seattle Cancer Care Alliance; University of Washington, Medical
Oncology Division; University of Washington, Department of Orthopedics and Sports Medicine; Seattle Children’s Hospital, Pediatric
Orthopedics, Seattle, WA, USA.
Received May 4, 2011; accepted June 22, 2011; Epub June 23, 2011; Published August 1, 2011
Abstract: Sarcomas are a biologically complex group of diseases that exhibit variable responses to single or combination therapy.
18F-FDG PET imaging contributes to sarcoma treatment response assessment as an objective semi-quantitative biomarker of
response. In this review, background and experience in 18F-FDG PET as a biomarker that successfully identifies tumor response is
assessed. (ajnmmi1105001).
Keywords: 18F-FDG PET, sarcoma, imaging treatment response
Full text PDF
Address all correspondence to:
Janet F. Eary, MD
University of Washington Medical Center
1959 NE Pacific St., Rm. AA011, Box 356113
Seattle, WA 98195-6113, USA.
E-mail: jeary@u.washington.edu
 |  |  |  |  |  |  |